Table 2.

Association of baseline plasma levels of soluble receptor for advanced glycation end products (sRAGE) with incident kidney disease^a

	Incident chronic kidney disease		Incident end-stage renal disease
	OR (95% CI)	P-value	HR (95% CI)	P-value
Model 1b	1.39 (1.06–1.83)	0.02	1.97 (1.47–2.64)	<0.001
Model 2c	1.22 (0.92–1.62)	0.16	1.08 (0.87–1.34)	0.49
Model 3d	1.37 (1.01–1.87)	0.04	1.01 (0.74–1.37)	0.9

CI, confidence interval; HR, hazard ratio; OR, odds ratio; sRAGE, soluble receptor for advanced glycation end products.

^aEstimates are expressed per one interquartile range (0.251 pg/mL) increase of log₁₀-transformed sRAGE. Interquartile range was calculated based on sRAGE distribution in the cohort random sample.

^bModel 1: Age, sex, race.

^cModel 2: Variables in Model 1 + baseline estimated glomerular filtration rate.

^dModel 3: Variables in Model 2 + β₂ microglobulin, β-trace protein, diabetes, high-density lipoprotein, body mass index, systolic blood pressure, current smoking status, C-reactive protein.